All In Biotech

Drug Trial Radar · NCT01492361

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)

Last checked: Nov 19, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,179

Actual

Start

Nov 2011

Primary completion

May 2018

Study completion May 2018

Sponsor

Lead sponsor
Amarin Pharma Inc.Industry
Sponsor type
Industry
First posted
Dec 15, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AMR101 (icosapent ethyl \[ethyl-EPA\]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.

Conditions

  • Cardiovascular Diseases

Interventions

  • AMR101Drug

    Parallel Assignment

  • PlaceboDrug

    Parallel Assignment

  • Statin therapyDrug

    Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.Time frame: Total follow-up time of up to approximately 6 years.

Locations

410 sites in 11 countries. Site status is shown where the registry gives one.

  • Amarin Investigational Site

    Birmingham, Alabama

  • Amarin Investigational Site

    Birmingham, Alabama

  • Amarin Investigational Site

    Huntsville, Alabama

  • Amarin Investigational Site

    Mobile, Alabama

  • Amarin Investigational Site

    Muscle Shoals, Alabama

  • Amarin Investigational Site

    Mesa, Arizona

  • Amarin Investigational Site

    Phoenix, Arizona

  • Amarin Investigational Site

    Tucson, Arizona

  • Amarin Investigational Site

    Little Rock, Arkansas

  • Amarin Investigational Site

    Beverly Hills, California

  • Amarin Investigational Site

    Chino, California

  • Amarin Investigational Site

    Concord, California

  • Amarin Investigational Site

    El Cajon, California

  • Amarin Investigational Site

    Encino, California

  • Amarin Investigational Site

    Fair Oaks, California

  • Amarin Investigational Site

    Hawaiian Gardens, California

  • Amarin Investigational Site

    Lancaster, California

  • Amarin Investigational Site

    Lincoln, California

  • Amarin Investigational Site

    Los Angeles, California

  • Amarin Investigational Site

    Los Angeles, California

  • Amarin Investigational Site

    Los Angeles, California

  • Amarin Investigational Site

    National City, California

  • Amarin Investigational Site

    Orange, California

  • Amarin Investigational Site

    Paramount, California

  • Amarin Investigational Site

    Roseville, California

  • Amarin Investigational Site

    San Diego, California

  • Amarin Investigational Site

    Torrance, California

  • Amarin Investigational Site

    Ventura, California

  • Amarin Investigational Site

    Walnut Creek, California

  • Amarin Investigational Site

    Aurora, Colorado

  • Amarin Investigational Site

    Colorado Springs, Colorado

  • Amarin Investigational Site

    Golden, Colorado

  • Amarin Investigational Site

    Guilford, Connecticut

  • Amarin Investigational Site

    Hartford, Connecticut

  • Amarin Investigational Site

    Newark, Delaware

  • Amarin Investigational Site

    Wilmington, Delaware

  • Amarin Investigational Site

    Washington D.C., District of Columbia

  • Amarin Investigational Site

    Boynton Beach, Florida

  • Amarin Investigational Site

    Bradenton, Florida

  • Amarin Investigational Site

    Clearwater, Florida

Showing 40 of 410 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.